Mobile App

Google Play Apple Store
New Insights in the Management of PH Associated with ILD: A Primer on Recognition, Severity Evaluation, and Treatment
AMA/ABS/ANCC/ACPE Activity - Video Lecture Library
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease (PH-ILD). Slides are developed and updated throughout the year by leading pulmonology expert physicians. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

The incidence of PH is known to increase among patients with ILD over the course of disease, however, there is a significant overlap of symptoms between fibrotic lung disease and PH. This is known to result in delayed detection and diagnosis. Clinicians need education on the signs and symptoms and how to screen for and detect PH early among patients with ILD. Although right heart catheterization is required to confirm the diagnosis of PH-ILD, other non-invasive and invasive approaches are useful in enabling an early and accurate diagnosis. Additionally, while there have been new insights into assessing and predicting the severity of PH among patients with ILD, mild PH among patients with ILD has been associated with poor outcomes. Identifying patients that have mild PH is therefore pivotal to improving outcomes with treatment. The development and approval of inhaled treprostinil has been an important milestone in PH-ILD. Indeed, new evidence and updates from ongoing clinical trials continue to be presented and published for the treatment of PH-ILD. To improve confidence among practitioners regarding the use of inhaled treprostinil, it is critical that they are abreast with the latest evidence and expert insights. In this on-demand video presentation Dr. Aaron Waxman will walk through examples of using and optimizing inhaled treprostinil therapy in clinical cases.
Review the activity and claim AMA, ABS, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.

Aaron Waxman, MD, PhD, FACP, FCCP Aaron Waxman, MD, PhD, FACP, FCCP
Executive Director, Center for Pulmonary Heart Disease
Brigham & Women's Hospital
Associate Professor of Medicine
Harvard Medical School

Supported by an independent educational grant from United Therapeutics, a public benefit company

Launch Date: June 27, 2024
Release Date: June 27, 2024
Expiration Date: May 31, 2025

Mini Module


Change Settings